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The diagnosis of incidental thyroid carcinoma in patients submitted to thyroidectomy for a benign dis-
ease is quite frequent. A retrospective analysis was performed on 455 patients submitted to surgical
intervention in order to establish the incidence of this kind of carcinoma. Two hundred ﬁfty-six patients
(56%) were affected by benign disease (176 multinodular goiter, 12 uninodular goiter, 1 Plummer disease
and 67 Basedow disease) and 202 (44%) by carcinoma. In 28 of 256 patients (11%), affected by benign
disease, occurred a histological diagnosis of thyroid carcinoma, (10 papillary carcinoma, 1 follicular
carcinoma, 29 papillary carcinoma follicular variant). In this study it's considered incidental thyroid
carcinoma the one occurred in patients who never underwent Fine Needle Aspiration (FNA) and there
were no suspicious features in all exams that may suggest the presence of carcinoma. Twenty-three of
the 40 incidental carcinoma (57.5%) were microcarcinomas. Ten patients had a sincronous carcinoma.
Actually, these patients are still in a follow up program and no recurrency of disease is occasionally
observed. This study shows that the only way to put doubts on the real benignity of the disease is the ﬁne
needle aspiration; there are no other instruments that could identify the occurrence of the carcinoma.
Moreover in the majority of cases the incidental carcinoma is a microcarcinoma, it doesn't reach sig-
niﬁcant volume, may be not centered by a FNA, but in most cases it’s not really biologically aggressive.
© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Thyroid nodular disease is extremely common; the incidence in
the adult population of the United States varies from 2% to 4%, but is
signiﬁcantly higher in goitrogenic areas [1].
Nodules may occur as single or multiple lesion, some may be
hypofunctioning compared to normal thyroid tissue, while others
show a normal activity or develop an autonomous functioning, not
subject to physiological regulation of the hypothalamic-pituitary-
thyroid axis [2].
A small percentage of thyroid nodules is represented by ma-
lignancies: approximately 1 nodule of 20 (5%) is a cancer.
Carcinomas of the thyroid are about 1% of all malignancies [3,4],
their annual incidence is 0.004% [4]. They are more frequent in
females, and although the main age of onset is between 40 and 60
years, they can also arise in childhood and youth [3]..
by Elsevier Ltd. All rights reservedThe incidence of thyroid carcinoma e particularly the follicular
histotype e is higher in goitrogenic regions, while papillary forms
are more common in areas where there are no conditions of iodine
deﬁciency.
The incidental ﬁnding of thyroid carcinoma in goiters is, without
doubt, an occurrence more common than in the past, due to the
improvement of diagnostic imaging [5], greater accuracy of the
histological technique and above all to the increased number of
thyroid diseases needing surgical treatment.
2. Materials and methods
From January 2010 to June 2013, 455 patients (363 females and
92 males, mean age 56.98 years, range 15e83) underwent thyroid
surgery. The operation performed was total thyroidectomy in 429
cases, lobectomy in 29.
Among the 455 observed patients 256 had a preoperative
diagnosis of benign thyroid disease: goiter in 188 cases (176 mul-
tinodular, 12 uninodular), Plummer's disease in 1, and Basedow
disease in 67. In 202 patients cytology led to the diagnosis of cancer.
A. Pezzolla et al. / International Journal of Surgery 12 (2014) S98eS102 S99or suspicious malignant lesion. Only the 256 patients who under-
went surgery for benign disease were included in this study.
All patients were studied by neck ultrasound prior to surgery,
and submitted to a CT scan of the chest in the case of plunging
goiter. In 11 patients a ﬁne needle aspiration (FNA) was performed,
excluding malignancy.
At the time of surgery all patients were euthyroid, and almost all
with no evidence of chronic thyroiditis.
The histological examination of the specimen conﬁrmed the
diagnosis of benign disease in 228 patients (89%). In 28 patients
(11%) the presence of 40 incidental carcinomatous lesions was
detected (10 patients with synchronous carcinoma).
The majority of patients with incidental carcinoma underwent
total thyroidectomy (27/28). In those previously submitted to lo-
bectomy (1/28), completion thyroidectomy was performed.
Histology detected a papillary cancer in 10 patients (25%),
follicular carcinoma in 1 (2.5%), follicular variant of papillary car-
cinoma in 29 (72.5%).
Referring to the “T” of TNM classiﬁcation, we had 23 micro-
carcinoma, 2 T1 carcinoma, 3 T2 carcinoma and 12 T3 carcinoma.
One of 12 patient with T3 carcinoma was T3N1.
Post-surgical treatments were entrusted to the endocrinologist
consultant on the basis of the histological result. All the patients
underwent to radioiodine metabolic therapy and were submitted
to follow-up: in the ﬁrst year after surgery annually dosage of
thyroglobulin (TG), cervical ultrasound, and a progressive reduction
of L-T4 dose leading from fully suppressive to half-suppressing ef-
fect (TSH levels maintained at 0.2e0.5 mU/l); further evaluation of
TG after stimulation test with recombinant human Thyroid-
Stimulating Hormone (rhTSH) was scheduled after 2 years.
At the moment, all patients are alive, apparently without local
recurrence or systemic progression of disease, and are still in the
course of follow-up.
3. Discussion
The thyroid carcinoma usually occurs as nodular disease. The
etiology is likely to be multifactorial, resulting from the complex
interaction between genetic, individual, and environmental risk
factors.
Although the pathogenetic role of the ionizing radiations is
currently well recognized [6], there is no signiﬁcative correlation
with prior radiotherapy if the thyroid tumor develops after the age
of 35, since the carcinogenic potential of the radiation treatment, if
performed at a later age, seems to decrease [7].
In about 3e5% of patients with thyroid carcinoma a family his-
tory for cancer of the thyroid is referred. Case in point is the asso-
ciation of medullary thyroid carcinoma with other
endocrinopathies in MEN-2 polyglandular syndrome [8,9].
Most incidental thyroid cancers reported in literature are
microcarcinomas. This term refers to a malignant lesion, predom-
inantly papillary, smaller or equal to 1 cm in diameter [10].
In the last years a signiﬁcant increase of this kind of neoplasm
has been detected, probably due to the widespread of ultrasound
examination as a ﬁrst-level diagnostic tool in the study of thyroid
diseases [11].
It is not yet been clariﬁed whether the microcarcinoma is a
distinct clinical entity characterized by a lower aggressiveness and
lesser growth potential, or instead it represents a subgroup of
differentiated thyroid carcinoma, diagnosed by chance when it is
smaller than 1 cm, during its evolution towards a clinically evident
cancer [12].
The prevailing current opinion is that the papillary micro-
carcinoma is a tumor characterized by an indolent trend of growth
and a very favorable prognosis; despite the uncertainty about itsnatural history has caused the lack of univocal and standardized
therapeutic approach [13,14].
Nevertheless in some authors’ opinion, the papillary micro-
carcinoma is a nosological entity characterized by a heterogeneous
clinical behavior, ranging from the small neoplastic outbreak acci-
dentally discovered after surgery for benign thyroid diseases, to
that of a cancer that is clinically manifested by the only presence of
metastasis to lymph nodes of the neck or at a distance.
The tumor, however, has a good prognosis. Recurrences are
mainly loco- regional and occur usually within the ﬁrst 10 years of
follow-up, with a prevalence oscillating between 1 and 10%. The
rate of mortality for microcarcinoma is very low, and reported with
a prevalence ranging between 0.2 and 2.2% [15].
Therefore, in patients at low risk of recurrence, as those with
incidental microcarcinoma, cervical ultrasonography and, to a
lesser extent, the basal dosage of serum TG may ensure a suitable
surveillance, even in the absence of ablation of residual thyroid
tissue. Moreover it is advisable to include in the protocol of con-
trols clinical examination, serum dosage of FT3, FT4, TSH, TG and
anti-TG antibodies (TGAb), in progress of hormone therapy
[16e18].
In patients with medium/high risk of recurrence who under-
went to ablative treatment of thyroid remnants, at a distance of
approximately 12 months after the demonstration of complete
ablation of thyroid tissue and undetectability of TG after maximum
stimulation of the hypophysis, is advisable to perform a cervical
ultrasound and the dosage of serum TG after stimulation of
endogenous TSH or e even better e after exogenous stimulation
with rhTSH.
The long-term follow-up of these patients shows that the risk of
recurrence is less than 2%, and the relapsing lesion may be early
detected by an ultrasonography of the neck [16].
Whilst our previous study showed a percentage of incidental
carcinomas (18.2%) e higher than that of other experiences [19] e
the current data, despite the greater number of patients (455 vs
240) report a lower value: 11%. This is due to the improvement and
more extensive employ of preoperative diagnostic techniques,
particularly the ﬁne needle aspiration and its cytological
interpretation.
This points out the importance of an accurate clinical and
instrumental diagnostic of thyroid nodules to differentiate benign
from malignant pathology.
For this purpose TSH, thyroid hormone, thyroglobulin, the
presence or absence of autoantibodies are ineffective [20].
Other biomarkers are provided by clinical and laboratory
research, aimed to the management of patients with thyroid neo-
plasms, applied in settings that vary from preoperative selection of
thyroid nodules for surgery to postoperative follow-up.
In particular molecular markers of thyroid tumors, derived from
genomic and proteomic methods, have been developed, but many
of these are too complex or expensive for routine clinical use or are
still poorly standardized [21e25].
One of the most interesting applications of biomarkers refers to
the employ on needle aspiration specimens. Fifty potential thyroid
tumor markers have been tested and ﬁve of these (galectin-3,
telomerase, thyroid peroxidase, RET-PTC, and p53) showed rela-
tively high accuracy for detecting malignancy in thyroid nodules
with indeterminate FNAB ﬁndings [26].
Galectin-3, the only submitted to wide multicenter studies
[27,28], usually is not expressed in normal thyroid tissue, while is
over-expressed in thyroid malignancy. Therefore it is considered an
accurate marker of early malignant transformation.
The highest value of speciﬁcity for galectin-3 to diagnose thy-
roid cancer nodules (97.2%) was shown using large needle aspira-
tion (LNA), that ensures to the analysis a larger tissue substrate
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galectin-3 immunodetection method [29,30].
Therefore, the use of LNA and galectin-3 detection on the aspi-
rate specimen, represents a promising way to optimize the pre-
operative selection of thyroid nodular lesions [25].
Further clinical trials are needed to determine the most cost-
effective protocol to utilize these diagnostic tools.
Thyroid ultrasound has been recognized as the main imaging
examination, because of its sensitivity, simplicity, and non-
invasiveness. It is the ﬁrst-line investigation, in the case of
nodular thyroid disease, as conﬁrmed in our experience. The use of
“small parts” probes at high frequency (12e15 MHz) achieves an
excellent representation of the anatomy of thyroid and surrounding
structures, and may detect very small lesions (2e3 mm) [31]. Un-
fortunately, despite of its high sensitivity in identifying lesions, the
thyroid ultrasound demonstrated an extremely low speciﬁcity.
Therefore it cannot be used for the ﬁnal discrimination between
benign and malignant nodules [32].
The nodular features that are usually assessed in the ultrasound
scan are the number, size, shape, echogenicity, structure, presence
of punctate calciﬁcations or shell calciﬁcations, perilesional halo,
margins and hematic ﬂow at echocolordoppler scan (ECDS). In
addition, are examined the regional lymph nodes, and can be
checked their dimensional changes over time.
Number and size of the nodules have no predictive value of
neoplasia; more frequently associated with thyroid tumors are the
relief of solid structure, anteroposterior diameter greater than the
latero-lateral one, hypoechoic, irregular or blurred margins, the
absence of halo, the presence of ﬁne calciﬁcation and only or pre-
dominantly intranodular vascularization. However none of these
characteristic has high sensitivity and high positive predictive value
[31,33].
Although the ultrasound examination of the nodule completed
with ECDS has a higher diagnostic accuracy in detecting the pres-
ence of central vascularization, its validity is still controversial,
since no type of ﬂow allows certainty diagnosis or rule out the
presence of cancer [31].
Elastography, an emerging ultrasound technique which mea-
sures tissue rigidity properties, showed higher stiffness indices for
thyroid cancers compared with benign nodules. Although prom-
ising as adjunctive tool for the diagnosis of thyroid malignancy,
especially in indeterminate nodules on cytology, larger and pro-
spective studies are needed to validate this new technique [34,35].
At present nor scintigraphy nor CT scan are able to solve the
problem of differential diagnosis of malignant and benign thyroid
nodules.
Recent studies on thyroid lesions detected incidentally at PET or
PET/CT in the course of follow-up for non-thyroid neoplasms,
showed higher Fluorine-18 ﬂuorodeoxyglucose (18F-FDG) uptake in
neoplastic compared to benign nodules [36], especially at a
threshold of 3.3 or more of maximum standardized uptake value
(SUVmax) [37]. In these patients themetabolic tumor volume (MTV)
measured by F-FDG PET/CT seems able to predict malignancies, and
better results are obtained referring to the combination of SUVmax
andMTV after stratiﬁcation of serum TSH levels [38]. Even the relief
on CT scan of calciﬁcations and focal uptake with high SUVmax
correlates with a high likelihood of thyroid cancer [39].
Otherwise some authors have reported that FDG accumulation
may be normal in the thyroid, such as a moderate to severe, diffuse
or focal, FDG activity [40].
Therefore, further studies are needed to state if 18F-FDG PET or
PET/CTmay be used in daily practice to identify malignancies in the
contest of benign thyroid diseases.
A further major clinical problem in the management of thyroid
nodules is the need of detecting the few malignant lesions in thecontext of a multinodular benign thyroid disease, so that the ﬁrst
may be initiated to adequate treatment and the latter may avoid
unnecessary surgery or take advantage of a “tailored” operation.
The cyto-ﬁne needle aspiration is the most accurate procedure
to determine whether a thyroid nodule shows elements of risk that
would justify surgical excision or if the probability of benignity is so
high to advise the simple clinical observation [41]. The surgical pre-
selection based on FNA reduces the need of surgery to less than 20%
of the nodular lesions, and over 50% of these prove to be malignant
at histology [42].
The only palpable thyroid nodules that do not require FNA are
those that shows an increased radioiodine uptake compared with
the surrounding parenchyma. These lesions are autonomously
functioning adenomas or hyperplastic functioning nodules, and
present an extremely low risk of malignancy.
The probability of ﬁnding a neoplastic outbreak in a multi-
nodular goiter does not substantially change compared to indi-
vidual solid nodules. Since ultrasound does not provide
information about the discriminatory nature of the nodule, these
lesions should be subjected to FNA [43e46].
The cytological diagnosis of malignancy is extremely accurate
when performed by an experienced thyroid cytopathologist (2e5%
false positives), his judgment of benignity is likewise reliable and
justiﬁes a conservative approach.
However, there are particular conditions in which surgical
excision may be indicated despite a negative cytology such as, for
example, in the case of scintigraphic uptake of 99 m Tc pertech-
netate or radioiodine at the level of the cervical lymph nodes or
family history of medullary thyroid carcinoma [47].
The cytological diagnosis of suspected malignancy is less spe-
ciﬁc, indicating a likelihood of malignancy ranging between 25%
and 75%.
In the presence of inconclusive cytology, clinical decision con-
cerning the excision or a conservative approach should be taken on
the basis of the available epidemiological, clinical, and instrumental
data. Limits, risks and beneﬁts of therapeutic options should never
be overlooked, but always explained and discussed with the patient
[48].
Thus, an aspect that emerges from our study is the complete lack
of data e medical history, ultrasound, scintigraphy e that could
reveal the presence of a tumor in the surgical specimen. In all pa-
tients with incidental carcinoma, the surgical indicationwas due to
the fact that the goiter had become symptomatic, or because thy-
roid function was compromised, or there was no response to
medical therapy or this treatment could not be continued anymore.
All these conditions were attributable to non-neoplastic diseases
that in some cases, being the contralateral thyroid lobe intact, we
treated with lobectomy and that we had to totalize in a second time
on the basis of the histological response.
Even in the presence of intraoperative dubious conditions e
such as a hard lump on palpation e we are used to perform the
lobectomy anyway, after achieving the patient informed consent
prior to surgery, since, according to the international literature,
extemporaneous histological examination is not indicated on the
thyroid.
In the management of thyroid nodular lesions the only reliable
test seems to be the ﬁne needle aspiration cytology, which, at least,
can put in doubt the supposed benignity. Our conﬁdence in the
method is strengthened by the fact that, to date, we have found
only two cases of false negative FNA.
Almost all authors agree on the indication to submit to FNA each
uninodular goiter, regardless of toxicity, ultrasound appearance,
vascularization, iodine uptake. Otherwise the same uniqueness of
views is not shared regarding the multinodulare goiter, which, in
our experience too, is not free of risk for cancer.
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a small part was subjected to FNA, precisely, only 2 of the 30 pa-
tients with incidental carcinoma, however unsuccessfully. This
conﬁrms the difﬁculty in recognizing in a multinodular goiter those
ultrasound and vascular aspects that may indicate the most sus-
picious nodule on which to perform the cytology. Moreover this
points out the major and persisting limit of ultrasound investiga-
tion, that remains an operator-dependent procedure, so that
different sonographers may sometimes express a diverging evalu-
ation of the same patient.
Therefore, we hope a closer collaboration between surgeon,
endocrinologist, radiologist, pathologist and nuclear medicine
specialist, to improve diagnostic accuracy, that could permit a
better deﬁnition of multinodular thyroid diseases, steer to the most
proper treatment e medical or surgical e and, in the latter case,
support the choice of the most suitable procedure for the patient.
A further debated question is the timing of surgery in patients in
progress of medical therapy for benign thyroid diseases.
Several considerations may oppose to delayed surgery. First of
all the frequency of incidental carcinomas.
Then the fact that modern surgery is safe in expert hands:
thyroidectomy is a poorly demolitive procedure, well standardized
(identiﬁcation of the recurrent nerves, preservation of the para-
thyroid glands), and possibly, in selected cases, may be performed a
mini-invasive video assisted approach.
Finally it should be considered the possibility of an easy
replacement therapy.
On the other hand, the incidental neoplastic lesion is almost
always a small cancer or a microcarcinoma, has poor biological
aggressiveness, and is susceptible to radioiodine metabolic therapy.
On the basis of these data, and according to our experience, we
believe reasonably acceptable a close follow-up performed by
surgeons and endocrinologists in patients with toxic multinodular
goiter, aimed to the early detection of malignancies.
4. Conclusions
Despite technical improvements of preoperative diagnostic, the
incidental thyroid carcinoma is still a common occurrence, and no
clinical or instrumental assessment has proved, till now, adequate
accuracy to identify malignancy, especially in the context of a
benign thyreopathy.
Ultrasound scan and FNA at present are the best diagnostic
means to study thyroid nodules and to select the indication and the
options to surgical treatment. Our experience demonstrates that a
slight margin of improvement is still possible, even working on
these two proven methods. Further enhancements are desirable,
and several proposals seem promising.
More sophisticated tools e elastosonography and 18F-FDG PET
or PET/CT e are still under evaluation. Finally recent studies are
trying to identify and develop new thyroid tumor markers aimed to
diagnostic and prognostic use.
In conclusion we recommend and once again emphasize the
need for a multispecialistic team to approach thyroid diseases, and
the need for establishing a relationship of trust with the patient,
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